NEW YORK (Reuters) – Drugmaker Valeant Pharmaceuticals will not see any changes to its planned refinancing in the wake of billionaire William Ackman and his hedge fund Pershing Square selling its share of the company, sources said.
LPC: Valeant refinancing on track despite Ackman stock sale
Mar 14, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital